Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Urol Int

Retrieve available abstracts of 56 articles:
HTML format
Text format



Single Articles


    December 2017
  1. OHLMANN CH, Gross-Langenhoff M
    Efficacy and Tolerability of Leuprorelin Acetate (Eligard(R)) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3- or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer.
    Urol Int. 2017 Dec 1. pii: 000479187. doi: 10.1159/000479187.
    PubMed     Text format     Abstract available


    November 2017
  2. HAMMERER PG, Wirth MP
    Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis.
    Urol Int. 2017 Nov 25. pii: 000479434. doi: 10.1159/000479434.
    PubMed     Text format     Abstract available


  3. ARTIBANI W, Porcaro AB, De Marco V, Cerruto MA, et al
    Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review.
    Urol Int. 2017 Nov 21. doi: 10.1159/000481438.
    PubMed     Text format     Abstract available


    October 2017
  4. TANG Y, Liu Z, Tang L, Zhang R, et al
    Significance of MRI/Transrectal Ultrasound Fusion Three-Dimensional Model-Guided, Targeted Biopsy Based on Transrectal Ultrasound-Guided Systematic Biopsy in Prostate Cancer Detection: A Systematic Review and Meta-Analysis.
    Urol Int. 2017 Oct 30. doi: 10.1159/000484144.
    PubMed     Text format     Abstract available


  5. YOO S, You D, Kim YS, Hong JH, et al
    Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Urol Int. 2017 Oct 12. doi: 10.1159/000481265.
    PubMed     Text format     Abstract available


    September 2017
  6. ZAPALA P, Dybowski B, Poletajew S, Radziszewski P, et al
    What Can Be Expected from Prostate Cancer Biomarkers? A Clinical Perspective.
    Urol Int. 2017 Sep 15. doi: 10.1159/000479982.
    PubMed     Text format     Abstract available


    July 2017
  7. VON HARDENBERG J, Schwartz M, Werner T, Fuxius S, et al
    Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review.
    Urol Int. 2017 Jul 13. doi: 10.1159/000477943.
    PubMed     Text format     Abstract available


  8. FAHMY O, Khairul-Asri MG, Hadi SHSM, Gakis G, et al
    The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.
    Urol Int. 2017 Jul 4. doi: 10.1159/000478789.
    PubMed     Text format     Abstract available


    June 2017
  9. BOESEN L, Norgaard N, Logager V, Balslev I, et al
    A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies.
    Urol Int. 2017 Jun 27. doi: 10.1159/000477214.
    PubMed     Text format     Abstract available


  10. MIYOSHI Y, Yoneyama S, Kawahara T, Hattori Y, et al
    Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
    Urol Int. 2017 Jun 14. doi: 10.1159/000477131.
    PubMed     Text format     Abstract available


    May 2017
  11. PORCARO AB, De Luyk N, Corsi P, Sebben M, et al
    Clinical Factors Predicting Bilateral Lymph Node Invasion in High-Risk Prostate Cancer.
    Urol Int. 2017 May 10. doi: 10.1159/000476039.
    PubMed     Text format     Abstract available


    April 2017
  12. CHOI H, Cho S, Bae JH, Lee SE, et al
    Characteristics of Prostate Cancer by Opportunistic Screening in Korean Men with a Prostate-Specific Antigen Level Less Than 4.0 ng per Milliliter.
    Urol Int. 2017 Apr 11. doi: 10.1159/000454886.
    PubMed     Text format     Abstract available


    March 2017
  13. PORCARO AB, de Luyk N, Corsi P, Sebben M, et al
    Clinical Factors Predicting and Stratifying the Risk of Lymph Node Invasion in Localized Prostate Cancer.
    Urol Int. 2017 Mar 1. doi: 10.1159/000458763.
    PubMed     Text format     Abstract available


  14. PORCARO AB, De Luyk N, Corsi P, Sebben M, et al
    Association between Basal Total Testosterone Levels and Tumor Upgrading in Low and Intermediate Risk Prostate Cancer.
    Urol Int. 2017 Mar 1. doi: 10.1159/000459632.
    PubMed     Text format     Abstract available


    February 2017
  15. SAKAI Y, Komai Y, Saito N, Ito M, et al
    Analysis of a Surgical Treatment for Persistent Urorectal Fistulas after Radical Cancer Surgery: A Comparison of Prostate Cancer and Rectal Cancer.
    Urol Int. 2017 Feb 24. doi: 10.1159/000457835.
    PubMed     Text format     Abstract available


  16. LEAO R, Domingos C, Figueiredo A, Hamilton R, et al
    Cancer Stem Cells in Prostate Cancer: Implications for Targeted Therapy.
    Urol Int. 2017 Feb 1. doi: 10.1159/000455160.
    PubMed     Text format     Abstract available


  17. MOSCHINI M, Shariat SF, Freschi M, Soria F, et al
    Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer.
    Urol Int. 2017 Feb 1. doi: 10.1159/000454736.
    PubMed     Text format     Abstract available


    January 2017
  18. POELAERT F, Kumps C, Lumen N, Verschuere S, et al
    Androgen Receptor Gene Copy Number and Protein Expression in Treatment-Naive Prostate Cancer.
    Urol Int. 2017 Jan 5. doi: 10.1159/000455158.
    PubMed     Text format     Abstract available


  19. ORBERGER M, Palisaar J, Roghmann F, Mittelstadt L, et al
    Association between the Surgical Apgar Score and Perioperative Complications after Radical Prostatectomy.
    Urol Int. 2017;98:61-70.
    PubMed     Text format     Abstract available


  20. KLEIN J, de Gorski A, Benamran D, Vallee JP, et al
    Transrectal Ultrasound-Guided Prostate Biopsy for Cancer Detection: Performance of 2D-, 3D- and 3D-MRI Fusion Targeted Techniques.
    Urol Int. 2017;98:7-14.
    PubMed     Text format     Abstract available


  21. HAAS M, Gunzel K, Miller K, Hamm B, et al
    Is the Ellipsoid Formula the New Standard for 3-Tesla MRI Prostate Volume Calculation without Endorectal Coil?
    Urol Int. 2017;98:49-53.
    PubMed     Text format     Abstract available


  22. GUNZEL K, Haas M, Maxeiner A, Stephan C, et al
    Predictive Parameters Identifying Men Eligible for a Sole MRI/Ultrasound Fusion-Guided Targeted Biopsy without an Additional Systematic Biopsy.
    Urol Int. 2017;98:15-21.
    PubMed     Text format     Abstract available


  23. SCHIFFMANN J, Larcher A, Sun M, Tian Z, et al
    Differences in Patient Characteristics among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice - Analysis of Surveillance, Epidemiology, and End Results Database.
    Urol Int. 2017;98:40-48.
    PubMed     Text format     Abstract available


  24. MENDEZ-RUBIO S, Salinas Casado J, Virseda Chamorro M, Gutierrez Martin P, et al
    Post Pelvic Radiotherapy Affectation of the Lower Urinary Tract Peripheral Innervation in Men.
    Urol Int. 2017;98:85-88.
    PubMed     Text format     Abstract available


  25. FOCARDI M, Bonelli A, Pinchi V, Vittori G, et al
    Hemidiaphragm Paralysis after Robotic Prostatectomy: Medical Malpractice or Unforeseeable Event?
    Urol Int. 2017;98:241-244.
    PubMed     Text format     Abstract available


  26. HIRASAWA Y, Yoshioka K, Nasu Y, Yamamoto M, et al
    Impact of Surgeon and Hospital Volume on the Safety of Robot-Assisted Radical Prostatectomy: A Multi-Institutional Study Based on a National Database.
    Urol Int. 2017;98:334-342.
    PubMed     Text format     Abstract available


  27. PEETERS C, Ponette D, van Poppel H
    Salvage Pelvic Lymph Node Dissection after Radical Prostatectomy for Biochemical and Lymph Node Recurrence.
    Urol Int. 2017;98:367-369.
    PubMed     Text format     Abstract available


  28. LAI P, Luo M, Hu G, Liu H, et al
    Primary Urothelial Carcinoma of the Prostate with Glandular Differentiation: A Case Report.
    Urol Int. 2017;98:370-372.
    PubMed     Text format     Abstract available


    November 2016
  29. PORCARO AB, Cavicchioli F, Mattevi D, De Luyk N, et al
    Clinical Factors of Disease Reclassification or Progression in a Contemporary Cohort of Prostate Cancer Patients Elected to Active Surveillance.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


    September 2016
  30. ZHU W, Xu H, Ma J, Guo J, et al
    An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


    July 2016
  31. MORAN PASCUAL E, Martinez Sarmiento M, Budia Alba A, Broseta Rico E, et al
    Central Body Fat Mass Measured by Bioelectrical Impedanciometry But Not Body Mass Index Is a High-Grade Prostate Cancer Risk Factor.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


  32. PORCARO AB, Novella G, Cacciamani G, De Marchi D, et al
    Prostate Volume Index Associates with a Decreased Risk of Prostate Cancer: Results of a Large Cohort of Patients Elected to a First Biopsy Set.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


    June 2016
  33. ODERDA M, Faletti R, Battisti G, Dalmasso E, et al
    Prostate Cancer Detection Rate with Koelis Fusion Biopsies versus Cognitive Biopsies: A Comparative Study.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


    April 2016
  34. ZHENG Y, Zhu C, Ma L, Shao P, et al
    miRNA-154-5p Inhibits Proliferation, Migration and Invasion by Targeting E2F5 in Prostate Cancer Cell Lines.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


  35. ALMEIDA GL, Petralia G, Ferro M, Ribas CA, et al
    Role of Multi-Parametric Magnetic Resonance Image and PIRADS Score in Patients with Prostate Cancer Eligible for Active Surveillance According PRIAS Criteria.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


    March 2016
  36. WEISS M, Ahrend H, Grossebrummel H, Ziegler P, et al
    Cytochrome P450 17A1 Inhibitor Abiraterone Acetate Counteracts the Heat Shock Protein 27's Cell Survival Properties in Prostate Cancer Cells.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


  37. PORCARO AB, Siracusano S, De Luyk N, Corsi P, et al
    Low-Risk Prostate Cancer and Tumor Upgrading to Higher Patterns in the Surgical Specimen. Analysis of Clinical Factors Predicting Tumor Upgrading to Higher Gleason Patterns in a Contemporary Series of Patients Who Have Been Evaluated According to the
    Urol Int. 2016.
    PubMed     Text format     Abstract available


    February 2016
  38. WANG J, Cheng G, Li X, Huang Y, et al
    Developing a Correct System to Evaluate the Accuracy of Gleason Score in Prostate Cancer of Chinese Population.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


  39. PORCARO AB, Petroziello A, Brunelli M, De Luyk N, et al
    High Testosterone Preoperative Plasma Levels Independently Predict Biopsy Gleason Score Upgrading in Men with Prostate Cancer Undergoing Radical Prostatectomy.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


    January 2016
  40. GAKIS G, Rink M, Fritsche HM, Graefen M, et al
    Prognostic Significance of Incidental Prostate Cancer at Radical Cystoprostatectomy for Bladder Cancer.
    Urol Int. 2016.
    PubMed     Text format     Abstract available


  41. ALCHIN DR, Murphy D, Lawrentschuk N
    What Are the Predictive Factors for Gleason Score Upgrade following RP?
    Urol Int. 2016;96:1-4.
    PubMed     Text format     Abstract available


  42. MARTORANA E, Ghaith A, Micali S, Pirola GM, et al
    A Retrospective Analysis of the Hemostatic Effect of FloSeal in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy.
    Urol Int. 2016;96:274-9.
    PubMed     Text format     Abstract available


  43. YAMADA Y, Fujimura T, Fukuhara H, Miyagawa J, et al
    Measuring Contact Pressure of Lower Extremities in Patients Undergoing Robot-Assisted Radical Prostatectomy.
    Urol Int. 2016;96:268-73.
    PubMed     Text format     Abstract available


  44. BIER S, Hennenlotter J, Rausch S, Aufderklamm S, et al
    Return to Work and Normal Daily Life Activity after Open and Robot-Assisted Radical Prostatectomy--A Single Surgeon Analysis.
    Urol Int. 2016;96:280-6.
    PubMed     Text format     Abstract available


  45. FROEHNER M, Propping S, Koch R, Borkowetz A, et al
    Is the Post-Radical Prostatectomy Gleason Score a Valid Predictor of Mortality after Neoadjuvant Hormonal Treatment?
    Urol Int. 2016;96:302-8.
    PubMed     Text format     Abstract available


  46. NIKLAS C, Saar M, Berg B, Steiner K, et al
    da Vinci and Open Radical Prostatectomy: Comparison of Clinical Outcomes and Analysis of Insurance Costs.
    Urol Int. 2016;96:287-94.
    PubMed     Text format     Abstract available


  47. SARKAR D, Ekwueme K, Parr N
    Patient-Reported Experience of Modified Transperineal Template Guided Saturation Biopsy Under General Anaesthesia and without Prophylactic Catheterisation.
    Urol Int. 2016;96:479-83.
    PubMed     Text format     Abstract available


  48. ANGULO JC, Lopez JI, Dorado JF, Sanchez-Chapado M, et al
    A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy.
    Urol Int. 2016;97:16-25.
    PubMed     Text format     Abstract available


  49. ROSENKRANTZ AB, Lepor H, Huang WC, Taneja SS, et al
    Practical Barriers to Obtaining Pre-Biopsy Prostate MRI: Assessment in Over 1,500 Consecutive Men Undergoing Prostate Biopsy in a Single Urologic Practice.
    Urol Int. 2016;97:247-8.
    PubMed     Text format    


  50. SCHIFFMANN J, Haese A, Lenz J, Heinzer H, et al
    Differences in Patient Characteristics Among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice at a European High-Volume Center.
    Urol Int. 2016;97:8-15.
    PubMed     Text format     Abstract available


    December 2015
  51. MAEDA Y, Kawahara T, Kumano Y, Ohtaka M, et al
    The Neutrophil-to-Lymphocyte Ratio before Repeat Prostate Needle Biopsy for Predicting Prostate Cancer.
    Urol Int. 2015.
    PubMed     Text format    


  52. UMBEHR MH, Luscher M, Hunziker R, Falkner F, et al
    Influence of Varying Assessment Parameters on the Diagnostic Accuracy of Magnetic Resonance Imaging in the Local Staging of Prostate Cancer.
    Urol Int. 2015.
    PubMed     Text format     Abstract available


  53. OZEL D, Duran Ozel B, Ozkan F
    Viscosity as a Biomarker Coincident with Shear Wave Elastography. Re: Prediction of Significant Prostate Cancer at Prostate Biopsy and Per Core Detection Rate of Targeted and Systematic Biopsies Using Real-Time Shear Wave Elastography (Urol Int 2015;
    Urol Int. 2015.
    PubMed     Text format    


    November 2015
  54. BUTOW Z, Schunk S, Janssen M, Graber S, et al
    Quality of Preoperative Biopsy Is a Risk Factor for Positive Surgical Margins in Organ-Confined Prostate Cancer Treated with Nerve-Sparing Robot-Assisted Radical Prostatectomy.
    Urol Int. 2015.
    PubMed     Text format     Abstract available


    January 2015
  55. GEIGER-GRITSCH S, Oberaigner W, Muhlberger N, Siebert U, et al
    Patient-Reported Urinary Incontinence and Erectile Dysfunction Following Radical Prostatectomy: Results from the European Prostate Centre Innsbruck.
    Urol Int. 2015.
    PubMed     Text format     Abstract available


  56. MATEI DV, Ferro M, Jereczek-Fossa BA, Renne G, et al
    Salvage radical prostatectomy after external beam radiation therapy: a systematic review of current approaches.
    Urol Int. 2015;94:373-82.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: